Nuvation Bio Inc. (NUVB) · Insider trading
What Nuvation Bio's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$118,250
1 insider, 1 trade
Sold, 12 months
$9.68M
6 insiders, 41% under a plan
Net, 12 months
−$9.56M
bought less sold
Latest filing
2026-08-21
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Hattersley GaryCHIEF SCIENTIFIC OFFICER | – | $3.88M | 4 | 2026-08-19 | 0 |
| Liu DongfangCHIEF MEDICAL OFFICER | – | $1.92M | 8 | 2026-04-17 | 18,000 |
| Hung DavidDirector, PRESIDENT AND CEO, 10% owner | $1.72M | – | 3 | 2025-06-16 | 59,281,054 |
| Wentworth KerryCHIEF REGULATORY OFFICER | $89,740 | $1.47M | 5 | 2026-06-23 | 53,000 |
| Hanley David C.CHIEF TECHNICAL OPERATIONS | – | $1.43M | 1 | 2025-11-19 | 24,000 |
| Markel StacyCHIEF PEOPLE OFFICER | $17,100 | $753,750 | 2 | 2026-06-23 | 32,591 |
| Sauvage PhilippeChief Financial Officer | $13,232 | $286,485 | 3 | 2026-06-23 | 12,673 |
| Mashal RobertDirector | $285,250 | – | 3 | 2026-06-09 | – |
| Wang Junyuan JerryDirector, CEO, ANHEART THERAPEUTICS LTD. | – | $162,883 | 1 | 2024-11-11 | 3,866,228 |
| Sjogren ColleenChief Commercial Officer | $90,500 | – | 1 | 2025-06-16 | 81,000 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-19 | Hattersley GaryCHIEF SCIENTIFIC OFFICER | Saleplan | 100,000 | 7.09 | $709,000 | 0 | Form 4 |
| 2026-06-23 | Wentworth KerryCHIEF REGULATORY OFFICER | Saleplan | 63,000 | 6.02 | $379,260 | 53,000 | Form 4 |
| 2026-06-23 | Markel StacyCHIEF PEOPLE OFFICER | Saleplan | 125,000 | 6.03 | $753,750 | 32,591 | Form 4 |
| 2026-06-23 | Sauvage PhilippeChief Financial Officer | Saleplan | 47,668 | 6.01 | $286,485 | 12,673 | Form 4 |
| 2026-06-09 | Mashal RobertDirector | Buyindirect | 25,000 | 4.73 | $118,250 | 225,000 | Form 4 |
| 2026-04-17 | Wentworth KerryCHIEF REGULATORY OFFICER | Saleplan | 36,750 | 5.01 | $184,118 | 53,000 | Form 4 |
| 2026-04-17 | Liu DongfangCHIEF MEDICAL OFFICER | Saleplan | 50,000 | 5.02 | $251,000 | 18,000 | Form 4 |
| 2026-04-06 | Wentworth KerryCHIEF REGULATORY OFFICER | Saleplan | 200,000 | 4.52 | $904,000 | 53,000 | Form 4 |
| 2025-12-01 | Liu DongfangCHIEF MEDICAL OFFICER | Sale | 150,000 | 7.82 | $1.17M | 18,000 | Form 4 |
| 2025-11-26 | Liu DongfangCHIEF MEDICAL OFFICER | Sale | 10,000 | 8.00 | $80,000 | 18,000 | Form 4 |
| 2025-11-25 | Liu DongfangCHIEF MEDICAL OFFICER | Sale | 10,000 | 7.50 | $75,000 | 18,000 | Form 4 |
| 2025-11-20 | Hattersley GaryCHIEF SCIENTIFIC OFFICER | Sale | 69,051 | 7.23 | $499,239 | 0 | Form 4 |
| 2025-11-20 | Hattersley GaryCHIEF SCIENTIFIC OFFICER | Sale | 300,000 | 7.23 | $2.17M | 0 | Form 4 |
| 2025-11-20 | Liu DongfangCHIEF MEDICAL OFFICER | Sale | 20,000 | 7.00 | $140,000 | 18,000 | Form 4 |
| 2025-11-19 | Hanley David C.CHIEF TECHNICAL OPERATIONS | Sale | 200,000 | 7.14 | $1.43M | 24,000 | Form 4 |
| 2025-11-19 | Liu DongfangCHIEF MEDICAL OFFICER | Sale | 15,000 | 5.10 | $76,500 | 18,000 | Form 4 |
| 2025-11-17 | Liu DongfangCHIEF MEDICAL OFFICER | Sale | 15,000 | 4.77 | $71,550 | 15,000 | Form 4 |
| 2025-10-27 | Hattersley GaryCHIEF SCIENTIFIC OFFICER | Saleplan | 100,000 | 5.02 | $502,000 | 0 | Form 4 |
| 2025-06-18 | Markel StacyCHIEF PEOPLE OFFICER | Buy | 10,000 | 1.71 | $17,100 | 29,591 | Form 4 |
| 2025-06-17 | Sauvage PhilippeChief Financial Officer | Buy | 4,000 | 1.79 | $7,160 | 9,902 | Form 4 |
| 2025-06-16 | Hung DavidDirector, PRESIDENT AND CEO, 10% owner | Buy | 500,000 | 1.79 | $895,000 | 59,281,054 | Form 4 |
| 2025-06-16 | Wentworth KerryCHIEF REGULATORY OFFICER | Buy | 26,000 | 1.79 | $46,540 | 26,000 | Form 4 |
| 2025-06-16 | Wentworth KerryCHIEF REGULATORY OFFICER | Buy | 24,000 | 1.80 | $43,200 | 50,000 | Form 4 |
| 2025-06-16 | Sjogren ColleenChief Commercial Officer | Buy | 50,000 | 1.81 | $90,500 | 81,000 | Form 4 |
| 2025-06-16 | Sauvage PhilippeChief Financial Officer | Buy | 3,300 | 1.84 | $6,072 | 5,902 | Form 4 |
| 2025-05-02 | Liu DongfangCHIEF MEDICAL OFFICER | Saleplan | 20,000 | 2.50 | $50,000 | 12,000 | Form 4 |
| 2025-04-07 | Hung DavidDirector, PRESIDENT AND CEO, 10% owner | Buy | 300,000 | 1.63 | $489,000 | 58,781,054 | Form 4 |
| 2025-04-04 | Hung DavidDirector, PRESIDENT AND CEO, 10% owner | Buy | 200,000 | 1.66 | $332,000 | 58,481,054 | Form 4 |
| 2025-04-01 | Mashal RobertDirector | Buyindirect | 1,100 | 1.67 | $1,837 | 101,100 | Form 4 |
| 2025-04-01 | Mashal RobertDirector | Buyindirect | 98,900 | 1.67 | $165,163 | 200,000 | Form 4 |
| 2024-11-11 | Wang Junyuan JerryDirector, CEO, ANHEART THERAPEUTICS LTD. | Sale | 56,361 | 2.89 | $162,883 | 3,866,228 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
22 × option exercise1 × grant or award
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-19 | Hattersley GaryCHIEF SCIENTIFIC OFFICER | Option exercise M | +100,000 | 1.87 | 100,000 | Form 4 |
| 2026-07-15 | Sauvage PhilippeChief Financial Officer | Option exercise M | +39,999 | 2.17 | 54,130 | Form 4 |
| 2026-07-15 | Sauvage PhilippeChief Financial Officer | Option exercise M | +1 | 1.97 | 54,131 | Form 4 |
| 2026-06-23 | Wentworth KerryCHIEF REGULATORY OFFICER | Option exercise M | +63,000 | 2.93 | 116,000 | Form 4 |
| 2026-06-23 | Markel StacyCHIEF PEOPLE OFFICER | Option exercise M | +90,380 | 1.87 | 122,971 | Form 4 |
| 2026-06-23 | Markel StacyCHIEF PEOPLE OFFICER | Option exercise M | +34,620 | 1.74 | 157,591 | Form 4 |
| 2026-06-23 | Sauvage PhilippeChief Financial Officer | Option exercise M | +47,668 | 2.17 | 60,341 | Form 4 |
| 2026-04-17 | Wentworth KerryCHIEF REGULATORY OFFICER | Option exercise M | +36,750 | 2.93 | 89,750 | Form 4 |
| 2026-04-17 | Liu DongfangCHIEF MEDICAL OFFICER | Option exercise M | +50,000 | 1.94 | 68,000 | Form 4 |
| 2026-04-06 | Wentworth KerryCHIEF REGULATORY OFFICER | Option exercise M | +100,000 | 1.87 | 153,000 | Form 4 |
| 2026-04-06 | Wentworth KerryCHIEF REGULATORY OFFICER | Option exercise M | +100,000 | 1.94 | 253,000 | Form 4 |
| 2026-02-27 | Makunje MosesSEE REMARKS | Grant or award A | +50,761 | – | 68,137 | Form 4 |
| 2025-12-01 | Liu DongfangCHIEF MEDICAL OFFICER | Option exercise M | +150,000 | 2.93 | 168,000 | Form 4 |
| 2025-11-26 | Liu DongfangCHIEF MEDICAL OFFICER | Option exercise M | +10,000 | 3.61 | 28,000 | Form 4 |
| 2025-11-25 | Liu DongfangCHIEF MEDICAL OFFICER | Option exercise M | +10,000 | 3.61 | 28,000 | Form 4 |
| 2025-11-20 | Hattersley GaryCHIEF SCIENTIFIC OFFICER | Option exercise M | +69,051 | 1.74 | 69,051 | Form 4 |
| 2025-11-20 | Hattersley GaryCHIEF SCIENTIFIC OFFICER | Option exercise M | +300,000 | 1.94 | 300,000 | Form 4 |
| 2025-11-20 | Liu DongfangCHIEF MEDICAL OFFICER | Option exercise M | +20,000 | 1.87 | 38,000 | Form 4 |
| 2025-11-19 | Hanley David C.CHIEF TECHNICAL OPERATIONS | Option exercise M | +200,000 | 1.87 | 224,000 | Form 4 |
| 2025-11-19 | Liu DongfangCHIEF MEDICAL OFFICER | Option exercise M | +15,000 | 1.87 | 30,000 | Form 4 |
| 2025-11-17 | Liu DongfangCHIEF MEDICAL OFFICER | Option exercise M | +15,000 | 1.87 | 30,000 | Form 4 |
| 2025-10-27 | Hattersley GaryCHIEF SCIENTIFIC OFFICER | Option exercise M | +100,000 | 1.74 | 100,000 | Form 4 |
| 2025-05-02 | Liu DongfangCHIEF MEDICAL OFFICER | Option exercise M | +20,000 | 1.94 | 32,000 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.